XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
The Company’s non-vested restricted stock that was granted prior to March 2015 is considered a participating security since the share-based awards contain a non-forfeitable right to dividends irrespective of whether the awards ultimately vest. Unvested share-based payment awards that contain non-forfeitable rights to dividends are participating securities and are included in the computation of earnings per share pursuant to the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings per share for common stock and any participating securities according to dividends declared (whether paid or unpaid) and participation rights in undistributed earnings.
(in thousands, except per common share data)
Three months ended September 30,
 
Nine months ended September 30,
2017
 
2016
 
2017
 
2016
Net income (loss) attributable to The Andersons, Inc.
$
2,533

 
$
1,722

 
$
(27,208
)
 
$
1,449

Less: Distributed and undistributed earnings allocated to nonvested restricted stock
—

 
2

 
—

 
7

Earnings (losses) available to common shareholders
$
2,533

 
$
1,720

 
$
(27,208
)
 
$
1,442

Earnings per share – basic:
 
 
 
 
 
 
 
Weighted average shares outstanding – basic
28,350

 
28,222

 
28,327

 
28,184

Earnings (losses) per common share – basic
$
0.09

 
$
0.06

 
$
(0.96
)
 
$
0.05

Earnings per share – diluted:
 
 
 
 
 
 
 
Weighted average shares outstanding – basic
28,350

 
28,222

 
28,327

 
28,184

Effect of dilutive awards
134

 
140

 
—

 
196

Weighted average shares outstanding – diluted
28,484

 
28,362

 
28,327

 
28,380

Earnings (losses) per common share – diluted
$
0.09

 
$
0.06

 
$
(0.96
)
 
$
0.05


There were 43 thousand antidilutive stock-based awards outstanding for the three months ended September 30, 2017. All outstanding share awards were antidilutive for the nine months ended September 30, 2017 as the Company experienced a net loss. There were no antidilutive stock-based awards outstanding for the three and nine months ended September 30, 2016.